WELL Health Technologies (TSE:WELL) Issues Earnings Results

WELL Health Technologies (TSE:WELL) posted its quarterly earnings data on Thursday. The company reported C$0.04 EPS for the quarter, FiscalAI reports. The firm had revenue of C$400.43 million for the quarter. WELL Health Technologies had a net margin of 1.82% and a return on equity of 3.15%.

Here are the key takeaways from WELL Health Technologies’ conference call:

• 2026 guidance was raised: Revenue guidance increased to CAD 1.58–1.65 billion, while adjusted EBITDA guidance rose to CAD 185–195 million. Management cited stronger June performance and higher-margin growth as the basis for the upgrade.
• Canadian operations reached the CAD 100 million adjusted EBITDA run rate milestone three quarters ahead of schedule. WELL Canada’s normalized Q2 adjusted EBITDA grew approximately 56%, supported by clinic growth, margin expansion, and technology-enabled productivity.
• WELL completed the acquisitions of Ontario Imaging Diagnostics and UnionMD, adding approximately CAD 22 million of annual EBITDA and expanding its diagnostics and procedural-health offerings. Management said both businesses performed at or above expectations in their first month.
• WELLSTAR raised CAD 50 million ahead of its expected TSX Venture listing in September, providing capital for acquisitions, AI product development, and organic growth. WELLSTAR generated Q2 revenue of CAD 23 million, up 37% year over year, with a 21% expected 2026 adjusted EBITDA margin.
• Reported Q2 adjusted EBITDA declined 3% to CAD 48.1 million and adjusted net income fell to CAD 11.6 million, while debt increased to CAD 628.7 million following acquisition funding. The company is also pursuing strategic alternatives for its U.S. care assets, but management cautioned that no transaction has reached a disclosure stage.

WELL Health Technologies Stock Performance

Shares of WELL opened at C$4.01 on Friday. The business’s fifty day moving average price is C$4.29 and its 200 day moving average price is C$4.15. WELL Health Technologies has a 12-month low of C$3.58 and a 12-month high of C$6.08. The stock has a market capitalization of C$1.02 billion, a PE ratio of 36.45, a price-to-earnings-growth ratio of -1.93 and a beta of 0.90. The company has a debt-to-equity ratio of 91.15, a current ratio of 0.83 and a quick ratio of 1.02.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently issued reports on WELL shares. Canaccord Genuity Group upped their target price on shares of WELL Health Technologies from C$6.50 to C$7.75 and gave the company a “buy” rating in a research note on Thursday, July 9th. Canadian Imperial Bank of Commerce lifted their price target on WELL Health Technologies from C$5.50 to C$6.00 and gave the stock an “outperformer” rating in a research note on Wednesday, June 3rd. Finally, Stifel Nicolaus lifted their price target on WELL Health Technologies from C$8.00 to C$8.25 and gave the stock a “buy” rating in a research note on Wednesday, June 3rd. Four research analysts have rated the stock with a Buy rating, Based on data from MarketBeat, WELL Health Technologies presently has a consensus rating of “Buy” and a consensus target price of C$7.12.

WELL Health Technologies Company Profile

WELL Health Technologies Corp. (TSX: WELL) is Canada’s largest outpatient healthcare company and a leading provider of technology-enabled healthcare solutions. WELL is building the infrastructure for a healthier Canada, where every patient gets better care, every provider is empowered by AI, and every piece of health data is protected. WELL owns and operates more than 250 clinics in Canada, supporting more than 5 million annual patient visits. Through its subsidiary WELLSTAR, WELL provides electronic medical records, AI-powered clinical tools, patient engagement platforms and IT management services.